Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Oncology Clinical Research Market Trends GLP-1 Drugs Regulatory Approval Obesity Treatment Regulatory Affairs Obesity Treatments

Lilly Turns GLP‑1 Cash Into Pipeline Push With Blockbuster Data and Vaccine Buys

The company’s recent clinical wins, platform acquisitions and insurer moves signal a coordinated push to build durable growth beyond obesity drugs.

Bepirovirsen Achieves Functional Cure in About One in Five Hepatitis B Patients

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Milestone Posts Q1 Loss as CARDAMYST Launch Shows Early Uptake and AFib-RVR Phase 3 Begins

PolyPid Nears Completion of Rolling FDA Filing for D‑PLEX100

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

Odyssey Therapeutics Shares Rise 11% in Nasdaq Debut After $279 Million IPO

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

Pfizer Beats Q1 Forecasts as Newer Drugs Offset COVID Slide

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Pfizer Tops Q1 Forecasts on Eliquis Strength, Reaffirms 2026 Outlook

Doctors Outline Safe Use of Peptides as FDA Weighs Easing Restrictions

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031